OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 (860) 240-0200
http://www.cga.ct.gov/ofa
SR-5
RESOLUTION APPROVING THE SETTLEMENT AGREEMENT IN
ROBERT BARFIELD, ET AL. V. ANGEL QUIROS, IN HIS OFFICIAL
CAPACITY AS COMMISSIONER, CONNECTICUT DEPARTMENT
OF CORRECTION.
Primary Analyst: ME 1/26/21
Contributing Analyst(s):
OFA Fiscal Note
State Impact:
Agency Affected Fund-Effect FY 20 $ FY 21 $ FY 22 $
Correction, Dept. GF - Cost 7,036,375 20,112,500 10,900,000
Note: GF=General Fund
Municipal Impact: None
Explanation
This settlement requires the Department of Correction (DOC) to
provide hepatitis C (HCV) screening and treatment to all inmates until
March 1, 2022 and pay the fees and costs for the class counsel resulting
in the costs described below.
FY 20:
The DOC spent $7.0 million on HCV testing and treatment.
1
FY 21:
The DOC was appropriated $20 million for HCV testing and
treatment
2
and pursuant to the settlement is required to pay $112,500
1
$10.1 million was appropriated for HCV testing and treatment within the Inmate
Medical Services (IMS) account in FY 20 and $7.0 million was expended. The
remaining balance was carried forward into FY 21 pursuant to CGS Sec. 4-89(c). The
total carry forward for the IMS account totaled $7.8 million and the entire carry
forward may or may not be used for HCV.
2
As of 10/31/20 the DOC has spent $2.9 million on HCV testing and treatment in FY
21. 2021SR-00005-R000001-FN.DOCX Page 2 of 2
in attorneys' fees and costs for class counsel.
FY 22:
HVC testing and treatment is anticipated to cost the agency
approximately $10.9 million until March 1, 2022, which is the end of
the settlement agreement.
3
The Out Years
None.
3
Full-year HCV testing and treatment is estimated to be $18.7 million per year.